Literature DB >> 28117384

Formalin disinfection of prostate biopsy needles may reduce post-biopsy infectious complications.

N Singla1, J Walker1, S L Woldu1, N M Passoni1, K de la Fuente1, C G Roehrborn1.   

Abstract

BACKGROUND: We sought to determine whether formalin disinfection of prostate biopsy needles between cores reduces post-biopsy urinary tract infections (UTIs).
METHODS: We reviewed a single-surgeon experience of transrectal prostate biopsies from 2010 to 2014. Biopsies were performed in either an operative suite, where 10% formalin was used to disinfect the needle tip between each biopsy core, or an outpatient clinic, where formalin was not used. Our primary outcome was post-biopsy UTI rates, defined as a positive urine culture within 30 days of biopsy. Infection severity was characterized by the need for admission. Patient demographics, prostate size, prior biopsies, prior UTIs, pre-biopsy antibiotics and cultures and post-biopsy cultures were analyzed. Logistic regression was used to assess predictors of post-biopsy UTIs. Statistical significance was defined as P<0.05.
RESULTS: A total of 756 patients were included for analysis, including 253 who received formalin disinfection and 503 who did not. Of these, 32 patients (4.2%) experienced post-biopsy UTIs, with 8 requiring admission (all without formalin use). Infection rates were more than double in the group that did not receive formalin (5.2% vs 2.3%, P=0.085). More patients in the formalin group had undergone prior biopsies (73.9% vs 31.8%, P<0.001). On multivariable analysis, prior UTI (odds ratio (OR) 3.77, P=0.006) was a significant predictor for post-biopsy infection, whereas formalin disinfection trended towards a protective effect (OR 0.41, P=0.055).
CONCLUSION: Infectious complications following prostate biopsy may be mitigated by the use of formalin disinfection of the biopsy needle between cores.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28117384      PMCID: PMC7224406          DOI: 10.1038/pcan.2016.70

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.554


  30 in total

1.  Fluoroquinolone-resistant E. coli in intestinal flora of patients undergoing transrectal ultrasound-guided prostate biopsy--should we reassess our practices for antibiotic prophylaxis?

Authors:  D Steensels; K Slabbaert; L De Wever; P Vermeersch; H Van Poppel; J Verhaegen
Journal:  Clin Microbiol Infect       Date:  2011-09-29       Impact factor: 8.067

2.  Should we change our prophylactic antimicrobial regimen for prostate biopsy?

Authors:  Margaret S Pearle
Journal:  J Urol       Date:  2011-02-22       Impact factor: 7.450

3.  Empirical management of urinary tract infections complicating transrectal ultrasound guided prostate biopsy.

Authors:  Raanan Tal; Pinhas M Livne; Dov M Lask; Jack Baniel
Journal:  J Urol       Date:  2003-05       Impact factor: 7.450

4.  Targeted antimicrobial prophylaxis using rectal swab cultures in men undergoing transrectal ultrasound guided prostate biopsy is associated with reduced incidence of postoperative infectious complications and cost of care.

Authors:  Aisha K Taylor; Teresa R Zembower; Robert B Nadler; Marc H Scheetz; John P Cashy; Diana Bowen; Adam B Murphy; Elodi Dielubanza; Anthony J Schaeffer
Journal:  J Urol       Date:  2012-02-16       Impact factor: 7.450

5.  Long-term fluoroquinolone use before the prostate biopsy may increase the risk of sepsis caused by resistant microorganisms.

Authors:  Bülent Akduman; Deniz Akduman; Hüsnü Tokgöz; Bülent Erol; Tuğrul Türker; Ferruh Ayoğlu; Necmettin Aydın Mungan
Journal:  Urology       Date:  2011-06-25       Impact factor: 2.649

6.  Cost-effectiveness of standard vs intensive antibiotic regimens for transrectal ultrasonography (TRUS)-guided prostate biopsy prophylaxis.

Authors:  Mehrad Adibi; Margaret S Pearle; Yair Lotan
Journal:  BJU Int       Date:  2011-11-24       Impact factor: 5.588

7.  Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy.

Authors:  Robert K Nam; Refik Saskin; Yuna Lee; Ying Liu; Calvin Law; Laurence H Klotz; D Andrew Loblaw; John Trachtenberg; Aleksandra Stanimirovic; Andrew E Simor; Arun Seth; David R Urbach; Steven A Narod
Journal:  J Urol       Date:  2013-01       Impact factor: 7.450

8.  Prevalence and significance of fluoroquinolone resistant Escherichia coli in patients undergoing transrectal ultrasound guided prostate needle biopsy.

Authors:  Michael A Liss; Alexandra Chang; Rosanne Santos; Amy Nakama-Peeples; Ellena M Peterson; Kathryn Osann; John Billimek; Richard J Szabo; Atreya Dash
Journal:  J Urol       Date:  2011-02-22       Impact factor: 7.450

9.  Is repeat prostate biopsy associated with a greater risk of hospitalization? Data from SEER-Medicare.

Authors:  Stacy Loeb; H Ballentine Carter; Sonja I Berndt; Winnie Ricker; Edward M Schaeffer
Journal:  J Urol       Date:  2012-10-09       Impact factor: 7.450

10.  Complication rate of transrectal ultrasound guided prostate biopsy: a comparison among 3 protocols with 6, 10 and 15 cores.

Authors:  Andreas P Berger; Christian Gozzi; Hannes Steiner; Ferdinand Frauscher; John Varkarakis; Hermann Rogatsch; Georg Bartsch; Wolfgang Horninger
Journal:  J Urol       Date:  2004-04       Impact factor: 7.450

View more
  1 in total

1.  Minimizing transrectal prostate biopsy-related infections; A prospective randomized trial of povidone-iodine intrarectal cleaning versus formalin needle disinfection.

Authors:  Rajesh Raj Bajpai; Shirin Razdan; Marcos A Sanchez-Gonzalez; Sanjay Razdan
Journal:  Indian J Urol       Date:  2021-07-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.